Contemporary Management of HIV: Emerging ART Paradigms

Supported by an educational grant from ViiV Healthcare.

Image: LANTERIA/Copyright©2017 Shutterstock Images LLC. All Rights Reserved Image: Rawpixel.com/Copyright©2017 Shutterstock Images LLC. All Rights ReservedImage: Christos Georghiou/Copyright©2017 Shutterstock Images LLC. All Rights ReservedImage: OPOLJA/Copyright©2017 Shutterstock Images LLC. All Rights Reserved

Provided by Clinical Care Options, LLC.

Tuesday, August 20, 201912:00PM (Local)Birmingham, AL

Use the Web Browser on Your Mobile Device to Participate in Polling*

Go to: pollev.com/CCO1

Or scan the QR code below

*All responses are anonymous and cannot be linked to individual participants.

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Staff Disclosures

The planners/managers reported the following relationships:

Ryan P. Topping, PhD; Jenny Schulz, PhD; Carolyn Skowronski, PharmD; Julie Skowronski, FNP-BC; and Edward King, MA, have no real or apparent conflicts of interest to report.

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME/CE services from Harmony Biosciences, Saluda Medical, and Shionogi.

Speaker and Disclosure Information

Roger Bedimo, MD, MS, FACPProfessor of Medicine Division of Infectious DiseasesUniversity of Texas Southwestern Medical CenterSection ChiefDivision of Infectious DiseasesDepartment of Internal MedicineVA North Texas Health Care SystemDallas, Texas

Roger Bedimo, MD, MS, FACP, has disclosed that he has received consulting fees from Gilead Sciences, Merck, Theratechnologies, and ViiV Healthcare and funds for research support from Bristol-Myers Squibb, Merck, and ViiVHealthcare.

Program Directors

Joseph J. Eron, Jr., MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North Carolina

Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DC

Program Directors Disclosures

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, and Merck.

Core Faculty

Eric S. Daar, MD Chief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, California

Core Faculty Disclosures

Eric S. Daar, MD, has disclosed that he has received consulting fees from Gilead Sciences and funds for research support from Gilead Sciences, Merck, and ViiV.

Disclosure of Unlabeled UseThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

GoalThe goal of this activity is to improve participants’ competence in providing optimal care for HIV-infected patients through the appropriate use of contemporary antiretroviral regimens.

Target AudienceThis program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for HIV-infected patients.

Learning Objectives

At the conclusion of this activity, participants should be able to:

▪ Incorporate data on evolving first-line treatment paradigms into the individualized care of HIV-infected patients, as appropriate

▪ Provide insightful counsel to patients and colleagues regarding emerging switch strategies for patients with HIV

▪ Evaluate the impact of clinical studies of investigational antiretroviral therapies and strategies on future patient management

Accreditation Information

In support of improving patient care, Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy Continuing Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008176-0000-19-004-L02-P).

Type of Activity: Application

Nursing Continuing Education

The maximum number of hours awarded for this activity is 1.0 contact hour.